Radioligand Therapy Targets in Endometrial Cancer
We screened every cell-surface protein with tumor immunohistochemistry data in endometrial cancer (including uterine endometrial carcinoma). 4,207 show detectable protein staining. Established and emerging radioligand targets expressed in endometrial cancer include EPCAM, HER3 (ERBB3), B7-H3 (CD276) and ITGAV. Below, we rank every candidate by tumor expression, internalization and clinical maturity.
Established and emerging radioligand targets in endometrial cancer
Targets already pursued with radioligands or other targeted modalities that show protein expression in endometrial cancer:
| Target | IHC in endometrial cancer | % positive | Internalizes |
|---|---|---|---|
| EPCAM | High (0.97) | 100% | — |
| HER3 (ERBB3) | High (0.82) | 100% | yes |
| B7-H3 (CD276) | High (0.77) | 100% | — |
| ITGAV | High (0.70) | 100% | — |
| c-MET (MET) | High (0.67) | 100% | yes |
| STEAP2 | High (0.64) | 100% | — |
| EGFR | Medium (0.48) | 73% | yes |
| Nectin-4 (NECTIN4) | Medium (0.47) | 90% | no |
| SSTR2 | Medium (0.33) | 73% | yes |
| CEA (CEACAM5) | Medium (0.30) | 56% | — |
| TMEFF2 | Medium (0.28) | 58% | — |
| Mesothelin (MSLN) | Medium (0.25) | 42% | yes |
| ITGB6 | Medium (0.24) | 46% | — |
| FAP | Medium (0.20) | 40% | yes |
| PSMA (FOLH1) | Low (0.18) | 27% | yes |
| DLK1 | Low (0.15) | 36% | — |
| HER2 (ERBB2) | Low (0.14) | 33% | yes |
| TROP2 (TACSTD2) | Low (0.11) | 33% | uncertain |
Top cell-surface targets for endometrial cancer radioligand therapy
A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.
| # | Target | IHC in endometrial cancer | % positive | Internalizes | Clinical stage |
|---|---|---|---|---|---|
| 1 | S1PR1 sphingosine-1-phosphate receptor 1 | High (0.79) | 100% | yes | Clinical |
| 2 | IGF1R insulin like growth factor 1 receptor | High (0.91) | 100% | yes | Clinical |
| 3 | HER3 (ERBB3) erb-b2 receptor tyrosine kinase 3 | High (0.82) | 100% | yes | Clinical |
| 4 | AMFR autocrine motility factor receptor | High (1.00) | 100% | yes | Discovery |
| 5 | c-MET (MET) MET proto-oncogene, receptor tyrosine kinase | High (0.67) | 100% | yes | Clinical |
| 6 | PTPN13 protein tyrosine phosphatase non-receptor type 13 | High (0.94) | 100% | yes | Discovery |
| 7 | IRAK4 interleukin 1 receptor associated kinase 4 | High (0.79) | 100% | yes | Clinical |
| 8 | GPR139 G protein-coupled receptor 139 | High (0.94) | 100% | yes | Discovery |
| 9 | FZD6 frizzled class receptor 6 | High (0.92) | 100% | yes | Discovery |
| 10 | HRH4 histamine receptor H4 | High (0.73) | 100% | yes | Clinical |
| 11 | MST1R macrophage stimulating 1 receptor | High (0.67) | 100% | yes | Clinical |
| 12 | FGFR1 fibroblast growth factor receptor 1 | High (0.64) | 100% | yes | Clinical |
| 13 | NR3C2 nuclear receptor subfamily 3 group C member 2 | High (0.82) | 100% | uncertain | Clinical |
| 14 | KCNG1 potassium voltage-gated channel modifier subfamily G member 1 | High (0.94) | 100% | — | Clinical |
| 15 | CYSLTR2 cysteinyl leukotriene receptor 2 | High (0.67) | 100% | yes | Discovery |
| 16 | IL1R2 interleukin 1 receptor type 2 | High (0.64) | 100% | yes | Discovery |
| 17 | EGFR epidermal growth factor receptor | Medium (0.48) | 73% | yes | Clinical |
| 18 | AGTRAP angiotensin II receptor associated protein | High (0.78) | 100% | yes | Discovery |
| 19 | FZD3 frizzled class receptor 3 | High (0.79) | 100% | yes | Discovery |
| 20 | NOTCH3 notch receptor 3 | High (0.64) | 91% | yes | Clinical |
| 21 | TREM1 triggering receptor expressed on myeloid cells 1 | High (0.76) | 100% | uncertain | Clinical |
| 22 | RNF43 ring finger protein 43 | High (1.00) | 100% | — | Discovery |
| 23 | M6PR mannose-6-phosphate receptor, cation dependent | High (0.78) | 100% | yes | Discovery |
| 24 | CHRNA7 cholinergic receptor nicotinic alpha 7 subunit | High (0.61) | 92% | yes | Clinical |
| 25 | AMDHD1 amidohydrolase domain containing 1 | High (1.00) | 100% | — | Discovery |
Internalizing receptors in endometrial cancer
Targets expressed in endometrial cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:
S1PR1 · IGF1R · HER3 (ERBB3) · AMFR · c-MET (MET) · PTPN13 · IRAK4 · GPR139 · FZD6 · HRH4 · MST1R · FGFR1
Endometrial Cancer targets already in clinical development
Targets with a clinical-stage drug program (any modality) that are also expressed in endometrial cancer. Clinical precedent lowers development risk but usually means more competition:
S1PR1 · IGF1R · HER3 (ERBB3) · c-MET (MET) · IRAK4 · HRH4 · MST1R · FGFR1 · NR3C2 · KCNG1 · EGFR · NOTCH3
How these endometrial cancer targets are ranked
Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in endometrial cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.
Rank endometrial cancer targets against your own criteria: isotope, organ limits, novelty.
Run a free endometrial cancer analysisRadioligand therapy targets in other cancers
- Prostate Cancer
- Neuroendocrine Tumors
- Lung Cancer
- Pancreatic Cancer
- Breast Cancer
- Ovarian Cancer
- Colorectal Cancer
- Kidney Cancer
- Bladder Cancer
- Gastric Cancer
- Liver Cancer
- Glioma
- Melanoma
- Head and Neck Cancer
- Thyroid Cancer
- Lymphoma
- Cervical Cancer
- Skin Cancer
- Testicular Cancer
Data sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.